Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more
Ultragenyx - Asset Resilience Ratio
Ultragenyx (RARE) has an Asset Resilience Ratio of 18.71% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Ultragenyx's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Ultragenyx's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $222.74 Million | 18.71% |
| Total Liquid Assets | $222.74 Million | 18.71% |
Asset Resilience Insights
- Good Liquidity Position: Ultragenyx maintains a healthy 18.71% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Ultragenyx Industry Peers by Asset Resilience Ratio
Compare Ultragenyx's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Ultragenyx (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Ultragenyx.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 29.02% | $436.30 Million | $1.50 Billion | +4.63pp |
| 2023-12-31 | 24.39% | $363.62 Million | $1.49 Billion | -15.39pp |
| 2022-12-31 | 39.78% | $614.82 Million | $1.55 Billion | +11.37pp |
| 2021-12-31 | 28.42% | $432.61 Million | $1.52 Billion | +0.68pp |
| 2020-12-31 | 27.73% | $488.01 Million | $1.76 Billion | -0.59pp |
| 2019-12-31 | 28.33% | $321.65 Million | $1.14 Billion | -19.80pp |
| 2018-12-31 | 48.12% | $346.27 Million | $719.56 Million | +20.82pp |
| 2017-12-31 | 27.31% | $134.00 Million | $490.75 Million | -13.21pp |
| 2016-12-31 | 40.51% | $219.03 Million | $540.63 Million | -20.86pp |
| 2015-12-31 | 61.37% | $343.43 Million | $559.57 Million | -21.05pp |
| 2014-12-31 | 82.42% | $163.16 Million | $197.97 Million | +5.39pp |
| 2013-12-31 | 77.03% | $45.95 Million | $59.65 Million | -- |